Takanori Matsubara
Oita University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Takanori Matsubara.
Oncology Reports | 2014
Liang Ma; Fuminori Sato; Ryuta Sato; Takanori Matsubara; Kenichi Hirai; Mutsushi Yamasaki; Toshitaka Shin; Tatsuo Shimada; Takeo Nomura; Kenichi Mori; Yasuhiro Sumino; Hiromitsu Mimata
Heat shock proteins (HSPs), which are molecular chaperones that stabilize numerous vital proteins, may be attractive targets for cancer therapy. The aim of the present study was to investigate the possible anticancer effect of single or dual targeting of HSP90 and HSP70 and the combination treatment with HSP inhibitors and chemotherapeutic agents in bladder cancer cells. The expression of HSP90 and the anticancer effect of the HSP90 inhibitor 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) coupled with cisplatin, docetaxel, or gemcitabine were examined using immunohistochemistry, quantitative real-time PCR, cell growth, flow cytometry, immunoblots and caspase-3/7 assays. The expression of HSP70 under HSP90 inhibition and the additive effect of HSP70 inhibitor pifithrin-μ (PFT-μ) were examined by the same assays and transmission electron microscopy. HSP90 was highly expressed in bladder cancer tissues and cell lines. 17-AAG enhanced the antiproliferative and apoptotic effects of each chemotherapeutic agent. 17-AAG also suppressed Akt activity but induced the upregulation of HSP70. PFT-μ enhanced the effect of 17-AAG or chemotherapeutic agents; the triple combination of 17-AAG, PFT-μ and a chemotherapeutic agent showed the most significant anticancer effect on the T24 cell line. The combination of 17-AAG and PFT-μ markedly suppressed Akt and Bad activities. With HSP90 suppression, HSP70 overexpression possibly contributes to the avoidance of cell death and HSP70 may be a key molecule for overcoming resistance to the HSP90 inhibitor. The dual targeting of these two chaperones and the combination with conventional anticancer drugs could be a promising therapeutic option for patients with advanced bladder cancer.
Oncology Reports | 2015
Ryuta Sato; Mutsushi Yamasaki; Kenichi Hirai; Takanori Matsubara; Takeo Nomura; Fuminori Sato; Hiromitsu Mimata
Angiopoietin-like proteins (ANGPTLs), which comprise 7 members (ANGPTL1-ANGPTL7), structurally resemble angiopoietins. We investigated the roles of ANGPTLs in the acquisition of androgen independence and the malignant behavior of human prostate cancer cells. Expression of ANGPTL messenger RNA (mRNA) and proteins were ascertained using RT-qPCR and western blot analysis in human prostate cancer cell lines. Androgen-dependent LNCaP and androgen-independent LNCaP/AI cells, respectively, were cultured in fetal bovine and charcoal-stripped medium. Cell proliferation, androgen dependence, migration and invasion, respectively, were examined under the overexpression and knockdown of ANGPTL2 by transfection of ANGPTL2 cDNA and its small-interfering RNA (siRNA). The effects of exogenous ANGPTL2 and blocking of its receptor, integrin α5β1, were also investigated. Human prostate cancer cell lines predominantly expressed ANGPTL2 among the members. Interrupting ANGPTL2 expression with siRNA suppressed the proliferation, migration and invasion of LNCaP cells. LNCaP/AI cells showed a higher ANGPTL2 expression than that of LNCaP cells. Furthermore, siRNA led to apoptosis of LNCaP/AI cells. The ANGPTL2-overexpressing LNCaP cells markedly increased proliferation, epithelial-to-mesenchymal transition (EMT) and malignant behavior in androgen-deprived medium. The migration rates were increased depending on the concentration of ANGPTL2 recombinant protein and were inhibited by anti-integrin α5β1 antibodies. To the best of our knowledge, this is the first study to elucidate the expression of ANGPTL2 in human prostate cancer cells. ANGPTL2 may be important in the acquisition of androgen independency and tumor progression of prostate cancer in an autocrine and/or paracrine manner via the integrin α5β1 receptor. Targeting ANGPTL2 may therefore be an efficacious therapeutic modality for prostate cancer.
Journal of Laparoendoscopic & Advanced Surgical Techniques | 2008
Fuminori Sato; Takeo Nomura; Toshitaka Shin; Kenichi Hirai; Takanori Matsubara; Yuji Hirata; Yoshihisa Tasaki; Hiromitsu Mimata
In this paper, we describe a case of ovarian vein syndrome (OVS) successfully treated with retroperitoneoscopic techniques. A 41-year-old woman complained with right flank pain, especially with a recumbent position. OVS was diagnosed and ureterolysis and ovarian vein resection were successfully performed, using retroperitoneoscopic techniques. The patient has been completely pain free for 36 months of follow-up. To our knowledge, no previous reports have described the retroperitoneoscopic treatment of OVS. With the minimally invasive approach, postoperative recovery and patient quality of life were markedly improved.
Urologia Internationalis | 1998
Hiromitsu Mimata; Yasuhiro Kasagi; Nobuyoshi Nasu; Takeo Nomura; Takanori Matsubara; Masayuki Nakagawa; Yoshio Nomura
The Biopty-gun is a useful tool in conducting percutaneous renal biopsies, but bleeding is still a significant complication. To reduce the rate of severe bleeding complications, we attempted a new method of renal needle biopsy using a retrograde access technique. Retrograde puncture of the renal calyx was performed using the Lawson nephrostomy kit. The 18-gauge needle of the Biopty-gun was inserted along the puncture wire and fired. A 7-french pigtail catheter was retained in the renal pelvis for a few days following the procedure. This biopsy is a promising and safe technique.
The Japanese Journal of Urology | 2015
Hiroyuki Fujinami; Tadamasa Shibuya; Kenichi Mori; Toshitaka Shin; Yasuhiro Sumino; Fuminori Sato; Hiromitsu Mimata; Yoshiyasu Sato; Takanori Matsubara; Sadaaki Sakamoto; Noritaka Kamei; Tetsuo Hongo
The Journal of Urology | 2012
Mutsushi Yamasaki; Takeo Nomura; Ryuta Sato; Kenichi Hirai; Takanori Matsubara; Fuminori Sato; Hiromitsu Mimata
Urology | 2011
Fuminori Sato; M. Liang; Kenichi Hirai; Takanori Matsubara; Takeo Nomura; Hiromitsu Mimata
The Journal of Urology | 2011
Kenichi Hirai; Takeo Nomura; Mutsushi Yamasaki; Takanori Matsubara; Fuminori Sato; Masatsugu Moriyama; Hiromitsu Mimata
Cancer Research | 2009
Mutsushi Yamasaki; Takeo Nomura; Takanori Matsubara; Kenichi Hirai; Fuminori Sato; Hiromitsu Mimata
西日本泌尿器科 | 2000
Takanori Matsubara; Yoshihisa Tasaki; Nobuyoshi Nasu; Hiromitsu Mimata; Yoshio Nomura